{"id":25251,"date":"2025-09-30T11:45:28","date_gmt":"2025-09-30T11:45:28","guid":{"rendered":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/lecanamab-controversial-alzheimers-drug-approved-by-australian-drugs-regulator-after-two-rejections\/"},"modified":"2025-10-01T14:16:17","modified_gmt":"2025-10-01T14:16:17","slug":"lecanamab-controversial-alzheimers-drug-approved-by-australian-drugs-regulator-after-two-rejections","status":"publish","type":"the-bmj-article","link":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/lecanamab-controversial-alzheimers-drug-approved-by-australian-drugs-regulator-after-two-rejections\/","title":{"rendered":"Lecanamab: Controversial Alzheimer\u2019s drug approved by Australian drugs regulator after two rejections"},"featured_media":0,"template":"","categories":[],"tags":[],"content_type":[32],"editorial_panel":[],"channel_page":[43],"class_list":["post-25251","the-bmj-article","type-the-bmj-article","status-publish","hentry","article-type-news","channel-page-news"],"aioseo_notices":[],"meta_box":{"the_bmj_article-url":"\/content\/390\/bmj.r2056","the_bmj_article-description":"","the_bmj_article-the_bmj_article_image":[{"width":150,"height":150,"file":"2025\/09\/Lecanemab_2W97C1K.jpg","filesize":175598,"sizes":{"medium":{"file":"Lecanemab_2W97C1K-300x194.jpg","width":300,"height":194,"mime-type":"image\/jpeg","filesize":24489,"url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2025\/09\/Lecanemab_2W97C1K-300x194.jpg"},"thumbnail":{"file":"Lecanemab_2W97C1K-150x150.jpg","width":150,"height":150,"mime-type":"image\/jpeg","filesize":19015,"url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2025\/09\/Lecanemab_2W97C1K-150x150.jpg"}},"image_meta":{"aperture":"0","credit":"Alamy Stock Photo","camera":"","caption":"2W97C1K A photo shows Lecanemab, sold under the brand name Leqembi, at a hospital in Itabashi Ward, Tokyo on December 25, 2023. Lecanemab is a monoclonal antibody medication used for the treatment of Alzheimer's disease. The drug was developed by Eisai and Biogen and subsequently approved in the United States and Japan.( The Yomiuri Shimbun via AP Images )","created_timestamp":"1703462400","copyright":"Credit: Associated Press \/ Alamy Stock Photo","focal_length":"0","iso":"0","shutter_speed":"0","title":"A photo shows Lecanemab, sold under the brand name Leqembi, at a hospital in Itabashi Ward, Tokyo on December 25, 2023. Lecanemab is a monoclonal antibody medication used for the treatment of Alzheimer's disease. The drug was developed by Eisai and Biogen","orientation":"1","keywords":["Medication","Alzheimers","disease","Dementia","Health","FIN","finance","HTH","health","SCI","science","LIF","life","lifestyle","medicine"]},"ID":"24992","name":"Lecanemab_2W97C1K.jpg","path":"\/dom34810\/wp-content\/uploads\/sites\/4\/2025\/09\/Lecanemab_2W97C1K.jpg","url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2025\/09\/Lecanemab_2W97C1K-150x150.jpg","full_url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2025\/09\/Lecanemab_2W97C1K.jpg","title":"A photo shows Lecanemab, sold under the brand name Leqembi, at a hospital in Itabashi Ward, Tokyo on December 25, 2023. Lecanemab is a monoclonal antibody medication used for the treatment of Alzheimer's disease. The drug was developed by Eisai and Biogen","caption":"2W97C1K A photo shows Lecanemab, sold under the brand name Leqembi, at a hospital in Itabashi Ward, Tokyo on December 25, 2023. Lecanemab is a monoclonal antibody medication used for the treatment of Alzheimer's disease. The drug was developed by Eisai and Biogen and subsequently approved in the United States and Japan.( The Yomiuri Shimbun via AP Images )","description":"","alt":"Lecanemab","srcset":false}],"the_bmj_article-related_articles":[],"the_bmj_article-journal_name":""},"head_tags":[{"tag":"title","content":"Lecanamab: Controversial Alzheimer\u2019s drug approved by Australian drugs regulator after two rejections | The BMJ"},{"tag":"meta","attributes":{"name":"robots","content":"max-image-preview:large"}},{"tag":"link","attributes":{"rel":"canonical","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/lecanamab-controversial-alzheimers-drug-approved-by-australian-drugs-regulator-after-two-rejections\/"}},{"tag":"meta","attributes":{"name":"generator","content":"All in One SEO (AIOSEO) 4.9.6.2"}},{"tag":"meta","attributes":{"property":"og:locale","content":"en_GB"}},{"tag":"meta","attributes":{"property":"og:site_name","content":"The BMJ | The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"property":"og:type","content":"article"}},{"tag":"meta","attributes":{"property":"og:title","content":"Lecanamab: Controversial Alzheimer\u2019s drug approved by Australian drugs regulator after two rejections | The BMJ"}},{"tag":"meta","attributes":{"property":"og:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/lecanamab-controversial-alzheimers-drug-approved-by-australian-drugs-regulator-after-two-rejections\/"}},{"tag":"meta","attributes":{"property":"article:published_time","content":"2025-09-30T11:45:28+00:00"}},{"tag":"meta","attributes":{"property":"article:modified_time","content":"2025-10-01T14:16:17+00:00"}},{"tag":"meta","attributes":{"name":"twitter:card","content":"summary"}},{"tag":"meta","attributes":{"name":"twitter:title","content":"Lecanamab: Controversial Alzheimer\u2019s drug approved by Australian drugs regulator after two rejections | The BMJ"}},{"tag":"link","attributes":{"rel":"alternate","type":"application\/rss+xml","title":"The BMJ \u00bb Feed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/feed\/"}},{"tag":"link","attributes":{"rel":"alternate","type":"application\/rss+xml","title":"The BMJ \u00bb Comments Feed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/comments\/feed\/"}},{"tag":"link","attributes":{"rel":"alternate","title":"oEmbed (JSON)","type":"application\/json+oembed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/oembed\/1.0\/embed?url=https%3A%2F%2Fbmj-chicken.bmj.com%2Fthebmj%2Fthe-bmj-article%2Flecanamab-controversial-alzheimers-drug-approved-by-australian-drugs-regulator-after-two-rejections%2F"}},{"tag":"link","attributes":{"rel":"alternate","title":"oEmbed (XML)","type":"text\/xml+oembed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/oembed\/1.0\/embed?url=https%3A%2F%2Fbmj-chicken.bmj.com%2Fthebmj%2Fthe-bmj-article%2Flecanamab-controversial-alzheimers-drug-approved-by-australian-drugs-regulator-after-two-rejections%2F&format=xml"}},{"tag":"link","attributes":{"rel":"https:\/\/api.w.org\/","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/"}},{"tag":"link","attributes":{"rel":"alternate","title":"JSON","type":"application\/json","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article\/25251"}},{"tag":"link","attributes":{"rel":"EditURI","type":"application\/rsd+xml","title":"RSD","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/xmlrpc.php?rsd"}},{"tag":"meta","attributes":{"name":"generator","content":"WordPress 6.9.4"}},{"tag":"link","attributes":{"rel":"shortlink","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/?p=25251"}},{"tag":"meta","attributes":{"property":"og:locale","content":"en_GB"}},{"tag":"meta","attributes":{"property":"og:site_name","content":"The BMJ"}},{"tag":"meta","attributes":{"property":"og:title","content":"Lecanamab: Controversial Alzheimer\u2019s drug approved by Australian drugs regulator after two rejections"}},{"tag":"meta","attributes":{"property":"og:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/lecanamab-controversial-alzheimers-drug-approved-by-australian-drugs-regulator-after-two-rejections\/"}},{"tag":"meta","attributes":{"property":"og:type","content":"article"}},{"tag":"meta","attributes":{"property":"og:description","content":"The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"name":"twitter:title","content":"Lecanamab: Controversial Alzheimer\u2019s drug approved by Australian drugs regulator after two rejections"}},{"tag":"meta","attributes":{"name":"twitter:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/lecanamab-controversial-alzheimers-drug-approved-by-australian-drugs-regulator-after-two-rejections\/"}},{"tag":"meta","attributes":{"name":"twitter:description","content":"The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"name":"twitter:card","content":"summary_large_image"}}],"_links":{"self":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article\/25251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article"}],"about":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/types\/the-bmj-article"}],"type":[{"embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/types\/the-bmj-article"}],"wp:attachment":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/media?parent=25251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/categories?post=25251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/tags?post=25251"},{"taxonomy":"article-type","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/content_type?post=25251"},{"taxonomy":"editorial-panel","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/editorial_panel?post=25251"},{"taxonomy":"channel-page","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/channel_page?post=25251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}